Current Clinical Trials

Breast Cancer Clinical Trials:

Alliance A011106 (ALTERNATE)
Alternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer Neo Adjuvant Treatment (ALTERNATE) in postmenopausal women: A phase III study

Amgen 20110147 (NOLAN)
Randomized, phase 2 study to estimate the effect of prophylactic intervention with naproxen or loratidine on bone pain in breast cancer subjects receiving chemotherapy and pegfilgrastim

AstraZeneca D699BC00001 (FALCON)
A randomized, double-blind, parallel-group, multicenter, phase III study to compare the efficacy and tolerability of Fulvestrant 500mg with anastrozole 1mg as hormonal treatment for postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy

Novartis CRAD001Y2201 (BOLERO-6)
A three-arm, randomized, open-label, multicenter phase II study investigating the combination of everolimus with exemestane versus everolimus alone versus capecitiabine in postmenopausal women with estrogen-receptor positive, HER2-negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole

Genentech ML28257 (SystHERs Registry) 
An observational cohort study of treatment patterns and outcomes in patients with HER2 positive metastatic breast cancer

Lung Cancer Clinical Trials:

Amgen 20120249
A randomized, multi-center phase 2 Trial of Denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer

Prostate Cancer Clinical Trials:

Alliance A031201
Phase III: Enzalutamide versus Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancer

Multiple Myeloma Clinical Trials:

Amgen 20090482
Randomized, double-blind multicenter study of Denosumab compared with zoledronic acid in the treatment of bone disease in subjects with newly diagnosed multiple myeloma

Celgene CC-4047-MM-014
Phase 2, multicenter, single-arm, open label study of Pomalidomide in combination with low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma following Lenolidomide plus Dexamethasone in the second-line setting

Website for all clinical trials:

If you require assistance navigating this website, or want more information about our clinical trials, please contact research manager Corilynn Hughes, R.N., B.S.N., O.C.N., at 410-871-6400.